- Home
- ABSI vs PHAT Comparison
ABSI vs PHAT Comparison
Compare ABSI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- PHAT
- Stock Information
- Founded
- ABSI 2011
- PHAT 2018
- Country
- ABSI United States
- PHAT United States
- Employees
- ABSI N/A
- PHAT N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- PHAT Health Care
- Exchange
- ABSI Nasdaq
- PHAT Nasdaq
- Market Cap
- ABSI 338.0M
- PHAT 289.0M
- IPO Year
- ABSI 2021
- PHAT 2019
- Fundamental
- Price
- ABSI $2.79
- PHAT $10.42
- Analyst Decision
- ABSI Strong Buy
- PHAT Strong Buy
- Analyst Count
- ABSI 5
- PHAT 5
- Target Price
- ABSI $8.40
- PHAT $16.40
- AVG Volume (30 Days)
- ABSI 2.9M
- PHAT 4.7M
- Earning Date
- ABSI 08-13-2025
- PHAT 08-07-2025
- Dividend Yield
- ABSI N/A
- PHAT N/A
- EPS Growth
- ABSI N/A
- PHAT N/A
- EPS
- ABSI N/A
- PHAT N/A
- Revenue
- ABSI $4,815,000.00
- PHAT $81,859,000.00
- Revenue This Year
- ABSI $81.76
- PHAT $195.45
- Revenue Next Year
- ABSI $287.79
- PHAT $106.76
- P/E Ratio
- ABSI N/A
- PHAT N/A
- Revenue Growth
- ABSI N/A
- PHAT 3055.70
- 52 Week Low
- ABSI $2.01
- PHAT $2.21
- 52 Week High
- ABSI $6.33
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- ABSI 47.46
- PHAT 78.59
- Support Level
- ABSI $2.65
- PHAT $4.47
- Resistance Level
- ABSI $2.87
- PHAT $11.28
- Average True Range (ATR)
- ABSI 0.19
- PHAT 1.45
- MACD
- ABSI -0.01
- PHAT 0.38
- Stochastic Oscillator
- ABSI 24.03
- PHAT 76.46
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.